Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning.

effect modifier individual participant data (IPD) meta-analysis subgroup effect treatment-covariate interaction

Journal

Statistics in medicine
ISSN: 1097-0258
Titre abrégé: Stat Med
Pays: England
ID NLM: 8215016

Informations de publication

Date de publication:
10 07 2020
Historique:
received: 26 09 2019
revised: 07 02 2020
accepted: 08 02 2020
pubmed: 1 5 2020
medline: 22 6 2021
entrez: 1 5 2020
Statut: ppublish

Résumé

Precision medicine research often searches for treatment-covariate interactions, which refers to when a treatment effect (eg, measured as a mean difference, odds ratio, hazard ratio) changes across values of a participant-level covariate (eg, age, gender, biomarker). Single trials do not usually have sufficient power to detect genuine treatment-covariate interactions, which motivate the sharing of individual participant data (IPD) from multiple trials for meta-analysis. Here, we provide statistical recommendations for conducting and planning an IPD meta-analysis of randomized trials to examine treatment-covariate interactions. For conduct, two-stage and one-stage statistical models are described, and we recommend: (i) interactions should be estimated directly, and not by calculating differences in meta-analysis results for subgroups; (ii) interaction estimates should be based solely on within-study information; (iii) continuous covariates and outcomes should be analyzed on their continuous scale; (iv) nonlinear relationships should be examined for continuous covariates, using a multivariate meta-analysis of the trend (eg, using restricted cubic spline functions); and (v) translation of interactions into clinical practice is nontrivial, requiring individualized treatment effect prediction. For planning, we describe first why the decision to initiate an IPD meta-analysis project should not be based on between-study heterogeneity in the overall treatment effect; and second, how to calculate the power of a potential IPD meta-analysis project in advance of IPD collection, conditional on characteristics (eg, number of participants, standard deviation of covariates) of the trials (potentially) promising their IPD. Real IPD meta-analysis projects are used for illustration throughout.

Identifiants

pubmed: 32350891
doi: 10.1002/sim.8516
pmc: PMC7401032
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2115-2137

Subventions

Organisme : Department of Health
ID : DRF-2018-11-ST2-077
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/21
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd.

Références

BMJ. 2017 Mar 3;356:j573
pubmed: 28258124
Stat Med. 2016 Mar 30;35(7):966-77
pubmed: 26415869
BMJ. 2017 Sep 13;358:j3932
pubmed: 28903924
BMC Med Res Methodol. 2011 Jun 20;11:94
pubmed: 21689447
Stat Med. 2003 Aug 30;22(16):2591-602
pubmed: 12898546
BMJ. 2006 May 6;332(7549):1080
pubmed: 16675816
Res Synth Methods. 2019 Sep;10(3):360-375
pubmed: 30523676
Stat Med. 2011 Sep 10;30(20):2481-98
pubmed: 21268052
Stat Med. 2011 Dec 10;30(28):3341-60
pubmed: 21953493
BMJ Open. 2016 Sep 08;6(9):e011148
pubmed: 27609843
Stat Med. 2014 Sep 28;33(22):3844-58
pubmed: 24789760
JAMA. 2007 Sep 12;298(10):1209-12
pubmed: 17848656
Stat Methods Med Res. 2013 Jun;22(3):324-45
pubmed: 22491174
Biom J. 2012 May;54(3):370-84
pubmed: 22685003
Stat Med. 2019 Feb 10;38(3):326-338
pubmed: 30284314
BMJ. 2004 Oct 23;329(7472):966-8
pubmed: 15499115
J Clin Oncol. 2008 Mar 20;26(9):1397-9
pubmed: 18349388
PLoS One. 2013 Apr 09;8(4):e60650
pubmed: 23585842
Nature. 2018 Nov;563(7733):619-621
pubmed: 30482931
Stat Med. 2008 May 20;27(11):1870-93
pubmed: 18069721
J Clin Epidemiol. 2004 Mar;57(3):229-36
pubmed: 15066682
Res Synth Methods. 2015 Jun;6(2):157-74
pubmed: 26099484
Int J Epidemiol. 2019 Apr 1;48(2):596-608
pubmed: 30445577
Stat Med. 2001 Aug 15;20(15):2219-41
pubmed: 11468761
Stat Med. 2018 Apr 30;37(9):1550-1561
pubmed: 29383818
J Clin Epidemiol. 2019 Oct;114:72-83
pubmed: 31195109
Environ Health Perspect. 1993 Dec;101 Suppl 4:59-66
pubmed: 8206043
BMJ. 2018 Dec 10;363:k4245
pubmed: 30530757
J Clin Epidemiol. 2007 Oct;60(10):1002-9
pubmed: 17884593
Hypertension. 2005 May;45(5):907-13
pubmed: 15837826
BMJ. 2003 Jan 25;326(7382):219
pubmed: 12543843
Syst Rev. 2014 May 20;3:46
pubmed: 24887172
Stat Med. 2012 Dec 20;31(29):3821-39
pubmed: 22807043
Stat Med. 2017 Jan 15;36(1):136-196
pubmed: 27488683
Int J Technol Assess Health Care. 2008 Summer;24(3):358-61
pubmed: 18601805
J Natl Cancer Inst. 1994 Jun 1;86(11):829-35
pubmed: 8182763
Stat Med. 2017 Feb 28;36(5):772-789
pubmed: 27910122
PLoS One. 2012;7(10):e46042
pubmed: 23056232
PLoS Med. 2015 Oct 13;12(10):e1001886
pubmed: 26461078
Stat Methods Med Res. 1997 Jun;6(2):167-83
pubmed: 9261914
BMJ. 2013 Feb 05;346:e5793
pubmed: 23386361
PLoS Med. 2015 Jul 21;12(7):e1001855
pubmed: 26196287
Int J Epidemiol. 2016 Dec 1;45(6):2075-2088
pubmed: 27375287
Stat Med. 2004 Aug 30;23(16):2509-25
pubmed: 15287081
J Clin Epidemiol. 2001 Aug;54(8):774-81
pubmed: 11470385
J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):137-159
pubmed: 19381330
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Stat Med. 2007 Jul 10;26(15):2982-99
pubmed: 17195960
Stat Med. 2017 Feb 28;36(5):855-875
pubmed: 27747915
Res Synth Methods. 2019 Dec;10(4):515-527
pubmed: 31111673
J Clin Epidemiol. 2015 Apr;68(4):470-4
pubmed: 25662008
J Clin Epidemiol. 2011 Sep;64(9):949-67
pubmed: 21411280
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
BMJ Open. 2014 Jan 27;4(1):e004188
pubmed: 24468721
Stat Med. 2020 Jul 10;39(15):2115-2137
pubmed: 32350891
Stat Med. 2001 Dec 30;20(24):3875-89
pubmed: 11782040
Ann Intern Med. 2011 May 17;154(10):680-3
pubmed: 21576536
Biometrics. 1946 Dec;2(6):110-4
pubmed: 20287815
BMC Med Res Methodol. 2019 Sep 2;19(1):183
pubmed: 31477023
Stat Med. 2006 Jan 15;25(1):127-41
pubmed: 16217841
BMC Med Res Methodol. 2018 May 18;18(1):41
pubmed: 29776399
BMJ. 2010 Mar 30;340:c117
pubmed: 20354011
Stat Med. 2010 Dec 20;29(29):3046-67
pubmed: 20827667
JAMA Intern Med. 2017 Apr 1;177(4):554-560
pubmed: 28192563
Lancet. 2005 Jan 22-28;365(9456):341-6
pubmed: 15664231
Stat Med. 2018 Dec 20;37(29):4404-4420
pubmed: 30101507
Stat Med. 2004 Aug 30;23(16):2567-86
pubmed: 15287085
Res Synth Methods. 2010 Jan;1(1):2-19
pubmed: 26056090

Auteurs

Richard D Riley (RD)

Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Staffordshire, UK.

Thomas P A Debray (TPA)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

David Fisher (D)

MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.

Miriam Hattle (M)

Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Staffordshire, UK.

Nadine Marlin (N)

Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Jeroen Hoogland (J)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Francois Gueyffier (F)

Inserm, Lyon, France.

Jan A Staessen (JA)

Department of Cardiovascular Sciences, Research Unit Hypertension and Cardiovascular Epidemiology, Studies Coordinating Centre, KU Leuven, Leuven, Belgium.

Jiguang Wang (J)

Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Karel G M Moons (KGM)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Johannes B Reitsma (JB)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Joie Ensor (J)

Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Staffordshire, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH